title: Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer.
abstract: BACKGROUND
  Elucidation of the biological features of triple negative breast cancer (TNBC) is important for deciding treatment strategies. The expression of a number of biomarkers in TNBC was analyzed to elucidate those features.
  
  
  METHODS
  The subjects were 134 TNBC patients. Immunohistochemical staining was employed to analyze for eight biomarkers: cytokeratin 5/6 (CK5/6), epidermal growth factor receptor (EGFR), p53, Ki-67 antigen (Ki-67), E-cadherin, N-cadherin, topoisomerase 2 alpha (TOP2A) and B-cell lymphoma 2 (BCL-2), which were then correlated with the nuclear grade (NG), tumor diameter, and the presence/absence of lymph node metastasis, distant recurrence and lymphatic infiltration.
  
  
  RESULTS
  Significantly more high than low NG TNBC exhibited positive p53, Ki-67, E-cadherin and TOP2A. High N-cadherin and TOP2A expression was shown significantly in TNBC with lymphatic infiltration, and N-cadherin was also significantly positively expressed in node metastasis-positive cases. EGFR and CK5/6 were positively expressed in high NG TNBC, but not significantly.
  
  
  CONCLUSIONS
  Analysis for expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A is meaningful for deciding treatment strategies for TNBC.
authors: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima, and Tokushima University Hospital, 3-18-15, Kuramoto-cho, Tokushima, 770-8503, Japan. kiramisa812@clin.med.tokushima-u.ac.jp
authors: Misako
authors: M
authors: Nakagawa
authors: Yoshimi
authors: Y
authors: Bando
authors: Taeko
authors: T
authors: Nagao
authors: Masami
authors: M
authors: Morimoto
authors: Chikako
authors: C
authors: Takai
authors: Takamasa
authors: T
authors: Ohnishi
authors: Junko
authors: J
authors: Honda
authors: Takuya
authors: T
authors: Moriya
authors: Keisuke
authors: K
authors: Izumi
authors: Masako
authors: M
authors: Takahashi
authors: Mitsunori
authors: M
authors: Sasa
authors: Akira
authors: A
authors: Tangoku
mesh_terms: D015703:Antigens, CD / Q000096:biosynthesis*; D000951:Antigens, Neoplasm / Q000096:biosynthesis*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D015820:Cadherins / Q000096:biosynthesis*; D004250:DNA Topoisomerases, Type II / Q000096:biosynthesis*; D004268:DNA-Binding Proteins / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000096:biosynthesis*; D008875:Middle Aged; D000075223:Poly-ADP-Ribose Binding Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
chemical_list: D015703:Antigens, CD; D000951:Antigens, Neoplasm; D015820:Cadherins; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D019394:Ki-67 Antigen; D000075223:Poly-ADP-Ribose Binding Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; C050361:CDH2 protein, human; C495901:TP53 protein, human; C000618811:TOP2A protein, human